Morphogenesis, and CohBar Announce Results from Phase 1b Trial of IFx-Hu2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
Portfolio Pulse from Benzinga Newsdesk
Morphogenesis and CohBar announce positive initial results from a Phase 1b trial of IFx-Hu2.0, a personalized cancer vaccine, in checkpoint inhibitor-resistant advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC).
June 05, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CohBar's stock may benefit from the positive initial results of the Phase 1b trial of IFx-Hu2.0, a personalized cancer vaccine.
CohBar is directly involved in the development of the IFx-Hu2.0 cancer vaccine, and positive initial results from the Phase 1b trial indicate potential for future success. This news may positively impact the company's stock price in the short term as investors react to the promising results.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100